About Torrent Pharmaceuticals Limited

The Torrent Group established Torrent Pharmaceuticals Limited in 1972 as its main business entity which focuses on developing and producing generic pharmaceutical formulations.  The company established the first Indian market segment strategy for pharmaceuticals and maintains leadership positions in Cardiovascular (CV) and Central Nervous System (CNS) and Vitamins Minerals Nutrients (VMN) and Gastro-Intestinal (GI) segments and operates in diabetology and cosmo-dermatology and pain management and anti-infective and gynaecology fields.The company operates throughout India and international markets through its Indian production sites and worldwide trading operations with major markets in India, Brazil, Germany and the United States. The company operates 18 subsidiaries including three step-down subsidiaries as of March 31, 2025 and established a Chilean subsidiary through full ownership on September 25, 2024.  

The company achieved a 7th position in the Indian pharmaceutical market and secured first place in Brazil and Germany while maintaining fifth position in Germany’s generic market and eleventh position in the US market for Indian pharmaceutical companies. 

Torrent Pharmaceuticals Limited’s Business Segments

The branded business segment generates 74% of the total company revenue. 

Revenue by geography (share of total):

•   India: 55%
•   USA: 10%
•   Germany: 10%
•   Brazil: 10%
•   Others: 15% .

Torrent Pharmaceuticals Limited Key Management

• Samir Mehta serves as the Executive Chairman of the company. 
• Aman Mehta serves as a Whole-time Director at the company.  
• Sudhir Menon serves as Executive Director (Finance) and Chief Financial Officer.  
• Chintan M. Trivedi serves as the Company Secretary. 

Latest Updates on Torrent Pharmaceuticals Limited

• The company launched Sitagliptin and Linagliptin in India after patent expiration and acquired Empagliflozin through licensing while expanding its Consumer Health Care (CHC) product range.  
• The company launched seven new prescription medications and two over-the-counter products in Germany which now represents 57% of the total generic market.  
• The company filed 97 new applications for Rest of World markets while adding 800+ field force members to its branded market operations.  
• The German market showed better performance than the market average with 7% growth while the US business experienced negative growth because of limited product launches and declining prices although new products will enter the market within two years to drive expansion.  
• The Brazilian real experienced an 11% depreciation throughout the year while insulin production at the facility required five months to adapt to European standards before returning to normal operations in Q4.  The company achieved a 32.3% Operating EBITDA margin and a 31% Return on Capital Employed (RoCE) ratio.  
• The debt-to-equity ratio reached 0.23 and net debt to EBITDA ratio reached 0.62x. 
• Expansion: A wholly owned subsidiary was incorporated in Chile on September 25, 2024, and market share improved in the branded generic markets of the Philippines, Malaysia, Sri Lanka and Mexico.
• Credit ratings: Long-term ratings of AA+ (ICRA, IND) and short-term rating of A1+ (ICRA) were reaffirmed.